Chartwell Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Chartwell Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$6.31M	Sell	6,002 -104	-2%	-$116K	0.22%	152
2024 Q2	$6.42M	Buy	6,106 +1,832	+43%	+$1.78M	0.23%	149
2024 Q1	$4.11M	Sell	4,274 -119	-3%	-$113K	0.14%	211
2023 Q4	$3.86M	Buy	4,393 +1,311	+43%	+$1.08M	0.14%	220
2023 Q3	$2.54M	Sell	3,082 -89	-3%	-$69.9K	0.1%	249
2023 Q2	$2.28M	Buy	3,171 +1,225	+63%	+$944K	0.08%	265
2023 Q1	$1.6M	Buy	+1,946	New	+$1.47M	0.06%	299

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chartwell Investment Partners's REGN Position: Q3 2024 in Review

Chartwell Investment Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 1.7% in Q3 2024, selling an estimated $116K and leaving 6,002 shares worth $6.31M. The position accounts for 0.22% of the portfolio, ranked #152.

Chartwell Investment Partners first reported a position in REGN in Q1 2023 and has held it in 7 quarters since. The position peaked at $6.42M in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Chartwell Investment Partners held 6,002 shares of Regeneron Pharmaceuticals worth $6.31M as of Q3 2024.
Chartwell Investment Partners sold 104 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $116K.
Regeneron Pharmaceuticals made up 0.22% of Chartwell Investment Partners's portfolio in Q3 2024, its #152 holding.
Chartwell Investment Partners first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
Chartwell Investment Partners's Regeneron Pharmaceuticals position peaked at $6.42M in Q2 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.